Skip to main content

Coya Therapeutics: An Attractive Valuation And First Set Of Data

Coya recent data in ALS seems under appreciated by the market and upcoming data in Alzheimer's offers the opportunity to confirm the early signals of efficacy in neurological conditions.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.